A Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

Brief description of study

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotoninnorepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) who had inadequate response to antidepressant therapy.

Detailed description of study

Participants will be randomized to receive: • Placebo + antidepressant (SSRI or SNRI) • Pimavanserin + antidepressant (SSRI or SNRI) The study duration will be up to 17 weeks.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Depression,Major depression,Depression,MajorDepressiveDisorder,depression
  • Age: Between 18 Years - 65 Years
  • Gender: All


Updated on 04 Jul 2023. Study ID: 826976

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center